VEGFA and metabolic dysfunction-associated steatohepatitis: It may affect the development of AS and NASH by inhibiting the proliferation, adhesion, and migration of vascular smooth muscle cells122, blocking the mevalonate pathway, decreasing hepatic TNF-α and VEGF expression, regulating cholesterol synthesis, and improving the lipid profile.